State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Keyuan Road 4, Gaopeng Street, Chengdu 610041, China.
Bioorg Med Chem. 2013 Nov 1;21(21):6844-54. doi: 10.1016/j.bmc.2013.02.002. Epub 2013 Feb 13.
A series of novel tubulin polymerization inhibitors (9a-9p) have been synthesized and evaluated for their in vitro and in vivo biological activities. Among these compounds, 9e displayed strong antiproliferative activity against several tumor cell lines (IC50=0.15-0.62μM). Compound 9e was also shown to arrest cells in the G2/M phase of the cell cycle and inhibit the polymerization of tubulin. Molecular docking studies suggested that 9e binds into the colchicine binding site of tubulin. In xenograft experiments, 9e exerted more potent anticancer effect than anticancer drug taxol against the H460 Human lung carcinoma in BALB/c nude mice. In summary, these findings suggest that 9e is a promising new antimitotic compound for the potential treatment of cancer.
一系列新型微管聚合抑制剂(9a-9p)已经被合成并评估了它们的体外和体内生物活性。在这些化合物中,9e 对几种肿瘤细胞系表现出很强的抗增殖活性(IC50=0.15-0.62μM)。化合物 9e 还能将细胞阻滞在细胞周期的 G2/M 期,并抑制微管的聚合。分子对接研究表明,9e 结合到微管的秋水仙碱结合位点。在异种移植实验中,9e 在 BALB/c 裸鼠的 H460 人肺癌中比抗癌药物紫杉醇发挥了更强的抗癌作用。总之,这些发现表明 9e 是一种很有前途的新型抗有丝分裂化合物,可用于癌症的潜在治疗。